#BEGIN_DRUGCARD DB01649

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
GTA
P1-7-METHYLGUANOSINE-P3-ADENOSINE-5',5'-TRIPHOSPHATE

# CAS_Registry_Number:
Not Available

# ChEBI_ID:
Not Available

# Chemical_Formula:
C21H30N10O17P3

# Chemical_IUPAC_Name:
2-amino-9-[(2R,3R,4S,5R)-5-({[({[({[(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}(hydroxy)phosphoryl)oxy](hydroxy)phosphoryl}oxy)(hydroxy)phosphoryl]oxy}methyl)-3,4-dihydroxyoxolan-2-yl]-7-methyl-6-oxo-6,7-dihydro-3H-1,3,7,9$l^{5}-purin-9-ylium

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Not Available

# Dosage_Forms:
Not Available

# Drug_Category:
Not Available

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Experimental
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
7-Methyl-Gpppa

# HET_ID:
GTA

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C21H29N10O17P3/c1-29-6-31(17-10(29)18(36)28-21(23)27-17)20-14(35)12(33)8(46-20)3-44-50(39,40)48-51(41,42)47-49(37,38)43-2-7-11(32)13(34)19(45-7)30-5-26-9-15(22)24-4-25-16(9)30/h4-8,11-14,19-20,32-35H,2-3H2,1H3,(H7-,22,23,24,25,27,28,36,37,38,39,40,41,42)/p+1/t7-,8-,11-,12-,13-,14-,19-,20-/m1/s1

# InChI_Key:
InChIKey=QQOHNVHGNZYSBP-XPWFQUROSA-O

# Indication:
Not Available

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
1649

# Mechanism_Of_Action:
Not Available

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
787.441

# Molecular_Weight_Mono:
787.10032412

# Organisms_Affected:
Not Available

# PDB_Experimental_ID:
1ST4

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
Not Available

# Pharmacology:
Not Available

# Predicted_LogP_Hydrophobicity:
-0.18

# Predicted_LogS:
-2.5

# Predicted_Water_Solubility:
2.89e+00 g/l

# Primary_Accession_No:
DB01649

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
446336

# PubChem_Substance_ID:
46507224

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
EXPT01652

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
CN1C=[N+]([C@@H]2O[C@H](CO[P@](O)(=O)O[P@](O)(=O)O[P@](O)(=O)OC[C@H]3O[C@H]([C@H](O)[C@@H]3O)N3C=NC4=C(N)N=CN=C34)[C@@H](O)[C@H]2O)C2=C1C(=O)N=C(N)N2

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:20:21 -0700

# Wikipedia_Link:
Not Available

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Cytoplasm. Nucleus

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
DCPS

# Drug_Target_1_GenBank_ID_Gene:
AY040773

# Drug_Target_1_GenBank_ID_Protein:
21654920

# Drug_Target_1_GeneCard_ID:
DCPS

# Drug_Target_1_Gene_Name:
DCPS

# Drug_Target_1_Gene_Sequence:
>1014 bp
ATGGCGGACGCAGCTCCTCAACTAGGCAAGAGGAAGCGCGAATTGGACGTGGAGGAGGCC
CACGCCGCCAGCACAGAGGAAAAGGAGGCAGGAGTTGGAAATGGTACCTGTGCTCCTGTC
CGCTTACCGTTCTCCGGCTTCAGACTGCAGAAGGTGCTGAGGGAGTCTGCGCGGGACAAA
ATCATTTTCCTACACGGGAAGGTGAATGAGGCCTCTGGGGATGGGGATGGAGAGGATGCC
GTTGTGATCCTGGAGAAGACGCCATTTCAGGTGGAACAGGTGGCTCAGCTCCTGACGGGC
AGCCCTGAGCTCCAATTGCAGTTCTCCAATGATATCTACAGCACCTATCACTTGTTCCCT
CCAAGACAACTGAATGATGTAAAGACGACCGTGGTTTACCCTGCCACAGAGAAACACCTG
CAGAAGTACCTGCGCCAGGACCTCCGCCTGATCCGAGAGACGGGAGATGACTACAGGAAT
ATTACTTTACCCCACCTGGAGTCCCAGAGCCTCAGCATCCAGTGGGTGTATAACATTCTC
GACAAGAAGGCTGAAGCGGACCGGATTGTTTTCGAGAACCCAGATCCCTCTGATGGTTTT
GTCCTCATCCCTGACCTCAAGTGGAACCAACAGCAGCTCGATGACTTGTACTTGATCGCC
ATCTGCCATCGCCGGGGCATCAGATCCCTACGCGACCTTACTCCGGAGCACTTGCCGCTG
CTCAGGAACATCCTCCACCAGGGGCAGGAGGCCATCCTGCAGCGCTACCGGATGAAGGGA
GACCATCTGCGAGTATACCTGCACTACCTGCCCTCCTACTACCACCTGCATGTGCACTTC
ACCGCCCTGGGCTTCGAGGCCCCCGGCTCAGGCGTGGAGCGGGCCCACCTGCTGGCTGAG
GTGATCGAGAACTTGGAGTGTGACCCTAGGCACTACCAGCAGCGCACGCTCACCTTCGCC
CTCAGGGCTGACGACCCCCTGCTCAAGCTCTTGCAGGAGGCTCAGCAAAGCTGA

# Drug_Target_1_General_Function:
Involved in mRNA degradation

# Drug_Target_1_General_References:
11042152	Zhang QH, Ye M, Wu XY, Ren SX, Zhao M, Zhao CJ, Fu G, Shen Y, Fan HY, Lu G, Zhong M, Xu XR, Han ZG, Zhang JW, Tao J, Huang QH, Zhou J, Hu GX, Gu J, Chen SJ, Chen Z: Cloning and functional analysis of cDNAs with open reading frames for 300 previously undefined genes expressed in CD34+ hematopoietic stem/progenitor cells. Genome Res. 2000 Oct;10(10):1546-60.
12198172	Liu H, Rodgers ND, Jiao X, Kiledjian M: The scavenger mRNA decapping enzyme DcpS is a member of the HIT family of pyrophosphatases. EMBO J. 2002 Sep 2;21(17):4699-708.
12871939	Kwasnicka DA, Krakowiak A, Thacker C, Brenner C, Vincent SR: Coordinate expression of NADPH-dependent flavin reductase, Fre-1, and Hint-related 7meGMP-directed hydrolase, DCS-1. J Biol Chem. 2003 Oct 3;278(40):39051-8. Epub 2003 Jul 18.

# Drug_Target_1_HGNC_ID:
HGNC:29812

# Drug_Target_1_HPRD_ID:
16787

# Drug_Target_1_ID:
2247

# Drug_Target_1_Locus:
11q24.2

# Drug_Target_1_Molecular_Weight:
38609

# Drug_Target_1_Name:
Scavenger mRNA-decapping enzyme DcpS

# Drug_Target_1_Number_of_Residues:
337

# Drug_Target_1_PDB_ID:
1XMM

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF05652	DcpS

# Drug_Target_1_Protein_Sequence:
>Scavenger mRNA-decapping enzyme DcpS
MADAAPQLGKRKRELDVEEAHAASTEEKEAGVGNGTCAPVRLPFSGFRLQKVLRESARDK
IIFLHGKVNEASGDGDGEDAVVILEKTPFQVEQVAQLLTGSPELQLQFSNDIYSTYHLFP
PRQLNDVKTTVVYPATEKHLQKYLRQDLRLIRETGDDYRNITLPHLESQSLSIQWVYNIL
DKKAEADRIVFENPDPSDGFVLIPDLKWNQQQLDDLYLIAICHRRGIRSLRDLTPEHLPL
LRNILHQGQEAILQRYRMKGDHLRVYLHYLPSYYHLHVHFTALGFEAPGSGVERAHLLAE
VIENLECDPRHYQQRTLTFALRADDPLLKLLQEAQQS

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Necessary for the complete degradation of mRNAs, both in normal mRNA turnover and in nonsense-mediated mRNA decay. Removes the 7-methyl guanine cap structure from mRNA fragments shorter than 10 nucleotides that are produced by 3'->5' exosome-mediated mRNA decay. Releases m7GMP. Can also degrade m7GDP to m7GMP. Has no activity towards mRNA molecules longer than 25 nucleotides

# Drug_Target_1_SwissProt_ID:
Q96C86

# Drug_Target_1_SwissProt_Name:
DCPS_HUMAN

# Drug_Target_1_Synonyms:
DCS-1
EC 3.-.-.-
HINT-5
Hint- related 7meGMP-directed hydrolase
Histidine triad protein member 5

# Drug_Target_1_Theoretical_pI:
6.35

# Drug_Target_1_Transmembrane_Regions:
None

# Drug_Target_2_Cellular_Location:
Cytoplasmic

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
EIF4E

# Drug_Target_2_GenBank_ID_Gene:
M15353

# Drug_Target_2_GenBank_ID_Protein:
306487

# Drug_Target_2_GeneCard_ID:
EIF4E

# Drug_Target_2_Gene_Name:
EIF4E

# Drug_Target_2_Gene_Sequence:
>654 bp
ATGGCGACTGTCGAACCGGAAACCACCCCTACTCCTAATCCCCCGACTACAGAAGAGGAG
AAAACGGAATCTAATCAGGAGGTTGCTAACCCAGAACACTATATTAAACATCCCCTACAG
AACAGATGGGCACTCTGGTTTTTTAAAAATGATAAAAGCAAAACTTGGCAAGCAAACCTG
CGGCTGATCTCCAAGTTTGATACTGTTGAAGACTTTTGGGCTCTGTACAACCATATCCAG
TTGTCTAGTAATTTAATGCCTGGCTGTGACTACTCACTTTTTAAGGATGGTATTGAGCCT
ATGTGGGAAGATGAGAAAAACAAACGGGGAGGACGATGGCTAATTACATTGAACAAACAG
CAGAGACGAAGTGACCTCGATCGCTTTTGGCTAGAGACACTTCTGTGCCTTATTGGAGAA
TCTTTTGATGACTACAGTGATGATGTATGTGGCGCTGTTGTTAATGTTAGAGCTAAAGGT
GATAAGATAGCAATATGGACTACTGAATGTGAAAACAGAGAAGCTGTTACACATATAGGG
AGGGTATACAAGGAAAGGTTAGGACTTCCTCCAAAGATAGTGATTGGTTATCAGTCCCAC
GCAGACACAGCTACTAAGAGCGGCTCCACCACTAAAAATAGGTTTGTTGTTTAA

# Drug_Target_2_General_Function:
Involved in RNA binding

# Drug_Target_2_General_References:
10856257	Dostie J, Ferraiuolo M, Pause A, Adam SA, Sonenberg N: A novel shuttling protein, 4E-T, mediates the nuclear import of the mRNA 5' cap-binding protein, eIF4E. EMBO J. 2000 Jun 15;19(12):3142-56.
11154262	Scheper GC, Morrice NA, Kleijn M, Proud CG: The mitogen-activated protein kinase signal-integrating kinase Mnk2 is a eukaryotic initiation factor 4E kinase with high levels of basal activity in mammalian cells. Mol Cell Biol. 2001 Feb;21(3):743-54.
11408474	Li W, Belsham GJ, Proud CG: Eukaryotic initiation factors 4A (eIF4A) and 4G (eIF4G) mutually interact in a 1:1 ratio in vivo. J Biol Chem. 2001 Aug 3;276(31):29111-5. Epub 2001 Jun 14.
11879179	Tomoo K, Shen X, Okabe K, Nozoe Y, Fukuhara S, Morino S, Ishida T, Taniguchi T, Hasegawa H, Terashima A, Sasaki M, Katsuya Y, Kitamura K, Miyoshi H, Ishikawa M, Miura K: Crystal structures of 7-methylguanosine 5'-triphosphate (m(7)GTP)- and P(1)-7-methylguanosine-P(3)-adenosine-5',5'-triphosphate (m(7)GpppA)-bound human full-length eukaryotic initiation factor 4E: biological importance of the C-terminal flexible region. Biochem J. 2002 Mar 15;362(Pt 3):539-44.
12975586	Miura T, Shiratori Y, Shimma N: Backbone resonance assignment of human eukaryotic translation initiation factor 4E (eIF4E) in complex with 7-methylguanosine diphosphate (m7GDP) and a 17-amino acid peptide derived from human eIF4GII. J Biomol NMR. 2003 Nov;27(3):279-80.
1672854	Ueda H, Iyo H, Doi M, Inoue M, Ishida T, Morioka H, Tanaka T, Nishikawa S, Uesugi S: Combination of Trp and Glu residues for recognition of mRNA cap structure. Analysis of m7G base recognition site of human cap binding protein (IF-4E) by site-directed mutagenesis. FEBS Lett. 1991 Mar 25;280(2):207-10.
1736299	Rychlik W, Domier LL, Gardner PR, Hellmann GM, Rhoads RE: Amino acid sequence of the mRNA cap-binding protein from human tissues. Proc Natl Acad Sci U S A. 1992 Feb 1;89(3):1148.
1993647	Marino MW, Feld LJ, Jaffe EA, Pfeffer LM, Han HM, Donner DB: Phosphorylation of the proto-oncogene product eukaryotic initiation factor 4E is a common cellular response to tumor necrosis factor. J Biol Chem. 1991 Feb 15;266(5):2685-8.
3112145	Rychlik W, Russ MA, Rhoads RE: Phosphorylation site of eukaryotic initiation factor 4E. J Biol Chem. 1987 Aug 5;262(22):10434-7.
3469651	Rychlik W, Domier LL, Gardner PR, Hellmann GM, Rhoads RE: Amino acid sequence of the mRNA cap-binding protein from human tissues. Proc Natl Acad Sci U S A. 1987 Feb;84(4):945-9.
7590282	Zhang Y, Klein HL, Schneider RJ: Role of Ser-53 phosphorylation in the activity of human translation initiation factor eIF-4E in mammalian and yeast cells. Gene. 1995 Oct 3;163(2):283-8.
7665584	Flynn A, Proud CG: Serine 209, not serine 53, is the major site of phosphorylation in initiation factor eIF-4E in serum-treated Chinese hamster ovary cells. J Biol Chem. 1995 Sep 15;270(37):21684-8.
7782323	Joshi B, Cai AL, Keiper BD, Minich WB, Mendez R, Beach CM, Stepinski J, Stolarski R, Darzynkiewicz E, Rhoads RE: Phosphorylation of eukaryotic protein synthesis initiation factor 4E at Ser-209. J Biol Chem. 1995 Jun 16;270(24):14597-603.
8505316	Kaufman RJ, Murtha-Riel P, Pittman DD, Davies MV: Characterization of wild-type and Ser53 mutant eukaryotic initiation factor 4E overexpression in mammalian cells. J Biol Chem. 1993 Jun 5;268(16):11902-9.
8521827	Haghighat A, Mader S, Pause A, Sonenberg N: Repression of cap-dependent translation by 4E-binding protein 1: competition with p220 for binding to eukaryotic initiation factor-4E. EMBO J. 1995 Nov 15;14(22):5701-9.
9878069	Pyronnet S, Imataka H, Gingras AC, Fukunaga R, Hunter T, Sonenberg N: Human eukaryotic translation initiation factor 4G (eIF4G) recruits mnk1 to phosphorylate eIF4E. EMBO J. 1999 Jan 4;18(1):270-9.

# Drug_Target_2_HGNC_ID:
HGNC:3287

# Drug_Target_2_HPRD_ID:
00591

# Drug_Target_2_ID:
1286

# Drug_Target_2_Locus:
4q21-q25

# Drug_Target_2_Molecular_Weight:
25097

# Drug_Target_2_Name:
Eukaryotic translation initiation factor 4E

# Drug_Target_2_Number_of_Residues:
217

# Drug_Target_2_PDB_ID:
1IPC

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF01652	IF4E

# Drug_Target_2_Protein_Sequence:
>Eukaryotic translation initiation factor 4E
MATVEPETTPTPNPPTTEEEKTESNQEVANPEHYIKHPLQNRWALWFFKNDKSKTWQANL
RLISKFDTVEDFWALYNHIQLSSNLMPGCDYSLFKDGIEPMWEDEKNKRGGRWLITLNKQ
QRRSDLDRFWLETLLCLIGESFDDYSDDVCGAVVNVRAKGDKIAIWTTECENREAVTHIG
RVYKERLGLPPKIVIGYQSHADTATKSGSTTKNRFVV

# Drug_Target_2_Reaction:
Not Available

# Drug_Target_2_Signals:
None

# Drug_Target_2_Specific_Function:
Recognizes and binds the 7-methylguanosine-containing mRNA cap during an early step in the initiation of protein synthesis and facilitates ribosome binding by inducing the unwinding of the mRNAs secondary structures

# Drug_Target_2_SwissProt_ID:
P06730

# Drug_Target_2_SwissProt_Name:
IF4E_HUMAN

# Drug_Target_2_Synonyms:
eIF-4E
eIF-4F 25 kDa subunit
eIF4E
mRNA cap-binding protein

# Drug_Target_2_Theoretical_pI:
6.04

# Drug_Target_2_Transmembrane_Regions:
None

#END_DRUGCARD DB01649
